http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
EVALUATION OF COMFORT OR PAIN BY V IRTUAL HUMAN IN USING OF SOME PRODUCT
( Yoshinori Maekawa ),( Bunzo Hasegawa ) 한국감성과학회 2002 춘계학술대회 Vol.2002 No.-
A virtual human which can evaluate Kansei such as comfort, pain, etc. when the virtual human uses some product is developed. In this paper, method of the evaluation of Kansei by the virtual human is presented. The body of our virtual human is modeled as an unifonn non-linear elastic one with a skeleton. The defonnation of the body on the contact with some product is simulated using a FEM analysis, and by using of the simulated results (load distribution, strain, etc.) on the contact surface the Kansei is predicted. As examples of the application, comfort of buttocks on seating and pain of ann on hanging of bag are shown. This virtual human can apply for the design of virtual products and also the simulation of medical care.
Maeda, Yutaka,Higo, Junki,Amagai, Yuri,Matsui, Jun,Ohkubo, Kei,Yoshigoe, Yusuke,Hashimoto, Masahiro,Eguchi, Kazuhiro,Yamada, Michio,Hasegawa, Tadashi,Sato, Yoshinori,Zhou, Jing,Lu, Jing,Miyashita, Tok American Chemical Society 2013 JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Vol.135 No.16
<P>This report describes a helicity-selective photoreaction of single-walled carbon nanotubes (SWNTs) with disulfide in the presence of oxygen. The SWNTs were characterized using absorption, photoluminescence (PL), Raman, and X-ray photoelectron spectroscopy, scanning electron microscopy, and current–voltage (<I>I</I>–<I>V</I>) measurements. Results showed remarkable helicity-selective (metallic SWNTs/semiconducting SWNTs and diameter) functionalization of SWNTs. The reaction rate decreases in the order of metallic SWNTs > semiconducting SWNTs and small-diameter SWNTs > large-diameter SWNTs. Control experiments conducted under various experimental conditions and ESR and femtosecond laser flash photolysis measurements revealed that the helicity-selective reaction proceeds via a photoinduced electron transfer reaction. The PL and <I>I</I>–<I>V</I> measurements showed that the photoreaction is effective not only to control SWNT conductivity but also for the band gap modulation of semiconducting SWNTs.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jacsat/2013/jacsat.2013.135.issue-16/ja402199n/production/images/medium/ja-2013-02199n_0012.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/ja402199n'>ACS Electronic Supporting Info</A></P>
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor
Takayoshi Nakamura,Nabeel Kajihara,Naoki Hama,Takuto Kobayashi,Ryo Otsuka,Nanumi Han,Haruka Wada,Yoshinori Hasegawa,Nao Suzuki,Ken-ichiro Seino 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.3
Objective: Breast cancer susceptibility gene 1 (BRCA1)-associated ovarian cancer patients have been treated with A poly (ADP-ribose) polymerase (PARP) inhibitor, extending the progression-free survival; however, they finally acquire therapeutic resistance. Interleukin (IL)-34 has been reported as a poor prognostic factor in several cancers, including ovarian cancer, and it contributes to the therapeutic resistance of chemotherapies. IL-34 may affect the therapeutic effect of PARP inhibitor through the regulation of tumor microenvironment (TME). Methods: In this study, The Cancer Genome Atlas (TCGA) data set was used to evaluate the prognosis of IL-34 and human ovarian serous carcinoma. We also used CRISPR-Cas9 genome editing technology in a mouse model to evaluate the efficacy of PARP inhibitor therapy in the presence or absence of IL-34. Results: We found that IL34 was an independent poor prognostic factor in ovarian serous carcinoma, and its high expression significantly shortens overall survival. Furthermore, in BRCA1-associated ovarian cancer, PARP inhibitor therapy contributes to anti-tumor immunity via the XCR1+ DC-CD8+ T cell axis, however, it is canceled by the presence of IL-34. Conclusion: These results suggest that tumor-derived IL-34 benefits tumors by creating an immunosuppressive TME and conferring PARP inhibitor therapeutic resistance. Thus, we showed the pathological effect of IL-34 and the need for it as a therapeutic target in ovarian cancer.
Acid-suppressive medication, a possible risk factor for asthma
( Yasuhiro Tomita ),( Yuma Fukutomi ),( Mari Irie ),( Kazuhiro Azekawa ),( Yoichi Nakamura ),( Chiharu Okada ),( Terufumi Shimoda ),( Miku Sano ),( Katsuyuki Kojima ),( Yoshinori Hasegawa ),( Masami T 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: Acid-suppressive medication (ASM), such as proton pump inhibitors and histamine 2 receptor antagonists, are commonly used. However, concerns have been raised that they might cause allergic diseases, including asthma. We investigated the relationship between the use of ASM and the subsequent incidence of asthma. Methods: A retrospective cohort study was conducted using the data from health insurance claims and results of specific health checkups for metabolic syndrome from 3 health insurance societies April 2011-thru-March 2015. Among the 40-64-year-old subjects without asthma (5,915 men, 3,973 women), logistic regression analyses were performed to investigate the relationship between the use of ASM (stratified as none, 1-59 days/year, ≥60days/year) and subsequent incidence of asthma. The adjustment was made for age, smoking status, BMI, and registered “allergic rhinitis” and “reflux esophagitis” diagnoses in multivariate logistic regression analyses. Results: 213 (3.6%) men (median 47 [IQR, 11] years old) and 211 (5.3%) women (median 47 [IQR, 9]) developed asthma. In the whole cohort, both short- and long-term use of ASM was significantly related to asthma incidence (adjusted Odds Ratio 1.89 [95% CI, 1.40-2.57]; P <0.001, aOR 1.82 [95% CI, 1.15-2.89]; P = 0.01, respectively). In men, only short-term use of ASM was significantly related to asthma incidence (aOR 1.87 [95% CI, 1.21-2.92]; P = 0.005). In women, both short- and long-term use was significantly related to asthma incidence (aOR 1.92 [95% CI, 1.26-2.92]; P = 0.002, aOR 2.85 [95% CI, 1.50-5.40]; P = 0.001, respectively). Longer duration of ASM use was also significantly associated with asthma incidence after adjusting for confounders (P-values for trends <0.001 in women and the whole cohort). Results in subjects without registered “reflux esophagitis” were almost the same as in the main analyses. Conclusions: Acid- suppressive medication could be a risk factor for the subsequent incidence of asthma.